MedTrace Logo

Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer

NCT00003418 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 4400

Last updated 2013-12-19

No results posted yet for this study

Summary

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane or tamoxifen may fight breast cancer by blocking the uptake of estrogen. It is not yet known whether exemestane is more effective than tamoxifen in treating breast cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of exemestane with that of tamoxifen in treating postmenopausal women with primary breast cancer who have already received 2-3 years of tamoxifen following surgery.

Conditions

Interventions

DRUG

exemestane

DRUG

tamoxifen citrate

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    collaborator NETWORK

  • UNICANCER

    collaborator OTHER

  • International Collaborative Cancer Group

    lead OTHER

Principal Investigators

  • R. Charles Coombes, MD, MRCP, FRCP, PhD, FMedSci · Charing Cross Hospital

  • Robert Paridaens, MD, PhD · University Hospital, Gasthuisberg

  • Moise Namer, MD, PhD · Centre Antoine Lacassagne

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-02-28

Countries

  • Belgium
  • France
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003418 on ClinicalTrials.gov